☆ 4.6 Article

Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial

CANCERS (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer

Zhengyu Yang et al.

Summary: This retrospective study compared the efficacy and safety of pembrolizumab plus chemotherapy and chemotherapy monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). The results showed that pembrolizumab plus chemotherapy achieved longer progression-free survival (PFS) and overall survival (OS) in the overall population. Subgroup analysis indicated that patients with positive PD-L1 expression, stage IV, good performance score (ECOG-PS <2), fewer comorbidities (simplified comorbidity score <9) or female patients benefited more significantly from pembrolizumab plus chemotherapy.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

The impact of the modified frailty index on clinical outcomes for patients with stage IV non-small cell lung cancer receiving chemotherapy

Shivani Mathur et al.

Summary: This study evaluates the impact of the Modified Frailty Index (mFI) on clinical outcomes for patients with metastatic non-small cell lung cancer (NSCLC). The results show no significant association between mFI score and overall chemotherapy toxicity. There were no significant differences in progression-free survival (PFS) and overall survival (OS) among frailty groups.

JOURNAL OF GERIATRIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

Fabrice Barlesi et al.

Summary: This study examines the application of metronomic oral vinorelbine in heavily pretreated patients with metastatic non-small cell lung cancer or pleural mesothelioma. The results show significant variability in drug exposure among patients, but satisfactory disease control rate and progression-free survival were achieved with manageable toxicities. Tumor burden, performance status, and neutrophils-to-lymphocyte ratio were associated with disease control rate, and NLR may serve as a predictive marker.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).

Herve Lena et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

S. M. Lee et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study

Yurie Seto et al.

Summary: This study aimed to identify predictive factors associated with overall survival in older patients with lung cancer, finding that performance status and albumin levels at diagnosis have the greatest impact on treatment outcomes. For patients aged 81 and above, careful consideration should be given to the indications for chemotherapy.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial

A. Camerini et al.

Summary: Metronomic oral vinorelbine significantly prolonged median progression-free survival without grade 4 toxicity in advanced NSCLC patients unfit for platinum combinations. Compared to the standard schedule, vinorelbine reduced toxicity.

ESMO OPEN (2021)

Add to Collection

Article Multidisciplinary Sciences

First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data

Shoko Noda-Narita et al.

Summary: Aging population has led to an increased prevalence of cancer among older adults. This study examined the prescribing patterns of first-line chemotherapy according to age, finding that the proportion of patients receiving chemotherapy decreased with age. Despite age differences, platinum doublets were identified as the most commonly prescribed regimen. Age did not solely influence regimen selection in this study.

PLOS ONE (2021)

Add to Collection

Article Oncology

Cancer statistics, 2020

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection

Article Oncology

Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC(double dagger) 04-2017)

Alain Vergnenegre et al.

FUTURE ONCOLOGY (2020)

Add to Collection

Article Oncology

Clinical prognostic model for older patients with advanced non-small cell lung cancer

Apar Kishor Ganti et al.

JOURNAL OF GERIATRIC ONCOLOGY (2019)

Add to Collection

Review Oncology

Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era

Alex Friedlaender et al.

CURRENT ONCOLOGY REPORTS (2019)

Add to Collection

Article Oncology

Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis

A. Camerini et al.

CLINICAL & TRANSLATIONAL ONCOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients

Haruna Kitazawa et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

D. Planchard et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol

Xavier Elharrar et al.

BMC CANCER (2016)

Add to Collection

Article Oncology

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

Romain Corre et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

Andrea Camerini et al.

BMC CANCER (2015)

Add to Collection

Article Oncology

Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?

Adrian G. Sacher et al.

CANCER (2015)

Add to Collection

Review Oncology

Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel

Filippo De Marinis et al.

CLINICAL LUNG CANCER (2015)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Review Oncology

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control

HK Weir et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)

Add to Collection

Article Oncology

Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases

E Radzikowska et al.

ANNALS OF ONCOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.